Caprock Group LLC Reduces Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Caprock Group LLC trimmed its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 24.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,598 shares of the biotechnology company’s stock after selling 3,505 shares during the period. Caprock Group LLC’s holdings in ADMA Biologics were worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ADMA. Aviance Capital Partners LLC purchased a new position in ADMA Biologics during the 3rd quarter valued at about $229,000. First Turn Management LLC purchased a new stake in ADMA Biologics in the 3rd quarter worth approximately $13,293,000. Thrivent Financial for Lutherans bought a new position in ADMA Biologics in the 3rd quarter valued at $3,802,000. Mutual of America Capital Management LLC purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at $701,000. Finally, Natixis Advisors LLC purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at $345,000. Institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

ADMA has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright raised their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, Raymond James boosted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Down 0.6 %

ADMA opened at $21.18 on Monday. The business’s fifty day simple moving average is $18.86 and its 200 day simple moving average is $14.89. ADMA Biologics, Inc. has a 52 week low of $3.60 and a 52 week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a market cap of $5.01 billion, a PE ratio of 75.64 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the firm posted $0.01 EPS. As a group, research analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 136,861 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the transaction, the director now directly owns 467,305 shares in the company, valued at $8,070,357.35. This trade represents a 22.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The trade was a 5.52 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 185,011 shares of company stock worth $3,255,204. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.